ArticleScientific reports2026
Oral immunization with filovirus-like particles partially protects IFNAR
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-adjuvanting Ebola virus-like particles that incorporate a cellular interferon-inducing domain.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ebola virus (EBOV), a member of the Filoviridae family, is responsible for severe hemorrhagic fever outbreaks with high case fatality rates in humans. Although injectable vaccines have shown efficacy, their deployment remains challenging in outbreak settings due to cold-chain requirements and the need for trained personnel. Oral vaccination offers an attractive alternative, combining ease of administration with the potential to induce both mucosal and systemic immunity. In this study, we evaluated the immunogenicity and protective efficacy of an orally-administered Ebola virus filovirus-like particle (EBOV-VLP) vaccine in type I interferon receptor-deficient (IFNAR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.